Navigation Links
AIDS Drug Found To Help Patients Undergoing Chemotherapy

Researchers say they discovered an anti-viral drug that helps reduce the risk of reactivating the hepatitis B virus in women who are being treated with chemotherapy for breast cancer.An estimated 12 percent // of breast cancer patients carry the hepatitis B virus and these patients are at risk of developing HBV reactivation during chemotherapy, which is a well-known complication resulting in varying degrees of liver damage that may lead to death.

Chemotherapy works by suppressing the immune system, which allows the HBV to replicate and spread through the blood stream. After chemotherapy is completed, the immune system recovers, and its attempt to clear HBV causes flare-ups of the virus.

Researchers say the anti-viral drug lamivudine can reduce the risk of HBV reactivation during and after chemotherapy. This drug was initially used for treating HIV in AIDS patients.

A recent study compared the incidence of HBV reactivation between chemotherapy patients receiving lamivudine and a control group. Only 7 percent of the chemotherapy patients taking lamivudine suffered HBV reactivation compared to 41 percent in the control group.Thus researchers say that these results show very clearly that prophylactic lamivudine significantly reduces the incidence of both HBV reactivation and hepatitis.

Thus , specialists say it would be better if breast cancer patients who are hepatitis B carriers should have anti-viral treatment before the start of chemotherapy.
'"/>




Page: 1

Related medicine news :

1. Fluoride Found Effective in Osteoporosis
2. Implantable Contact Lens Found Safe and Effective
3. Cancer hazard Found With Animal-Based Nutrients
4. Processed Meat, Diabetes connection Found
5. Night Time Aspirin Regimen Found to Reduce Blood Pressure
6. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
7. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
8. Preventive Therapies Found to be More Effective in Managing Migraines
9. Common Cold Found to Fight Cancer
10. Circumcision Found To Prevent HIV Spread
11. Drug Found To Reduce The Transmission Of Herpes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: